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Background: Platinum-based therapy in combination with 5-fluorouracil with cetuximab
has shown the best survival in pts with recurrent/metastatic squamous cell carcinoma of
the head and neck (R/M SCCHN). The purpose of this study is to evaluate the efficacy and
tolerability of carboplatin, pemetrexed and to assess differential outcomes in patients with
oropharyngeal primary and HPV related disease.
Patients and Methods: The charts of consecutive patients with R/M SCCHN were
reviewed. All patients receiving at least one cycle of the two-drug regimen (pemetrexed
500 mg/m2, carboplatin area under the curve of five intravenously), were included for
assessment of response, safety, toxicity, and survival.
Results:A total of 86 patients received this regimen between January 2008 and December
2012, of which, 63 were included in this analysis. Forty-one percent (26) of the patients had
cancers of the oropharynx, and of those, 50% had HPV-positive disease, 32% (20) had can-
cers of the larynx, and 24% (15) of the oral cavity. Median number of cycles administered
was 4 (range 1–14 cycles) with 50% of the patients receiving four or more cycles. Half the
patients achieved stable disease as their best response, 8% (5) attained a partial response,
24% progressed on therapy, and the remaining patients (12) could not have their response
assessed. On the basis of Kaplan–Meier analysis, median progression-free survival (PFS)
was 5.1 months (95% CI 3.2, 6.2) and median overall survival (OS) was 9.4 months (95%
CI 4.3, 13.1). Among pts with oropharyngeal primary (n=26), median PFS was 6.4 months
(95% CI 2.8, 7.9) and median OS was 16.6 months (95% CI 9.6, 19.5). Among HPV+ pts
(n=13), median PFS was 7.0 months (95% CI 4.8, ne) and median OS was 17.1 months
(95% CI 11.2, 21.7).
Conclusion: Combination carboplatin-pemetrexed is an effective and well-tolerated treat-
ment, associated with a median PFS of 5.1 months and a clinical benefit in at least 57%
of the patients treated.
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INTRODUCTION
To date, there are few therapies that provide significant survival
benefit in patients with recurrent/unresectable or metastatic squa-
mous cell cancer of the head and neck (R/M SCCHN). The current
standard of care for patients with good performance status (PS)
is platinum-based chemotherapy, typically in combination with
5-FU or taxol. Median survival reported with these combinations
is in the realm of 7–8 months (1). More recently, the median sur-
vival was noted to be increased to 10 months with addition of
cetuximab to a chemotherapy doublet backbone. However, this
increased survival came at the cost of adding a third agent to
the treatment regimen and the possibility of additional toxicity
(2). Pemetrexed is an inhibitor of thymidylate synthase, as well as
other folate-dependent enzymes now used in management of vari-
ous malignancies (3, 4). Pemetrexed was initially approved in 2004
as a single agent for second line treatment of metastatic non-small
cell lung cancer (NSCLC) (5). It has shown efficacy in treatment of
patients with non-squamous NSCLC, now considered standard of
care for upfront management of metastatic disease in combination
with carboplatin (6, 7). It is very well tolerated even when used for
a prolonged period of time as a maintenance therapy in patients
with NSCLC (8). This drug has been evaluated in setting of head
and neck cancers, the results, however, have not been consistent
across studies (9–12).
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In a recent phase III trial, Urba and colleagues compared peme-
trexed in combination with cisplatin to cisplatin alone in patients
with R/M SCCHN. While the combination of cisplatin plus peme-
trexed did not result in improvement in the overall survival (OS)
or progression-free survival (PFS) for all patients included in the
analysis, the pre-defined subgroup analysis did demonstrate posi-
tive results among patients with a better performance status (PS)
and patients with an oropharyngeal primary (12). In patients with
PS 0–1, pemetrexed plus cisplatin significantly improved the OS
(8.4 months compared to 6.7 months with cisplatin alone, HR
0.83, 95% CI 0.7–0.98, p= 0.026). This is likely due to the ability
of this group of patients to better tolerate a combination regimen
compared to patients with PS 2 or greater. Given the improved
outcomes in patients with a better PS, many contemporary studies
only include patients with a PS of 0–1.
We at our institution have been using pemetrexed in combi-
nation with carboplatin in patients with R/M SCCHN, who are
candidates for salvage chemotherapy and have witnessed com-
parable outcomes with this regimen to standard of care; and
improved tolerability. In this population with metastatic/recurrent
disease, maintaining quality of life is of paramount importance.
This regimen is associated with excellent tolerability and conve-
nience, without a requirement for prolonged infusion (as needed
with 5-Fluorouracil) or the risk of neuropathy as is associated with
paclitaxel.
PATIENT AND METHODS
ELIGIBILITY
All patients treated for R/M SCCHN at the University of Michi-
gan between Jan 2008 and Dec 2012 were identified and their
medical records were reviewed. All patients who received at least
one cycle of carboplatin-pemetrexed were included for assessment
of response, safety, and tolerability. A total of 86 patients were
treated with this regimen during this period. Eligibility for cyto-
toxic therapy and this regimen in particular was determined by the
treating oncologist. Sixty-three of the 86 patients were included for
this analysis. Patients with another concurrent malignancy and
patients with a primary malignancy of the salivary glands, skin,
sinus, or nasopharynx were excluded from the analysis.
STUDY DESIGN AND TREATMENT
In this single-center retrospective review, the goal was to analyze
the outcomes in all patients with SCCHN, treated with this novel
regimen during the designated period, and to assess its efficacy
and tolerability outside the clinical trial setting.
The primary endpoint of our analysis was to determine PFS and
OS. Secondary endpoints included response rate, clinical benefit
rate, effect of HPV status and primary site on survival, and assess-
ment of adverse effects (grade ≥2). Relevant patient information
was obtained from our Epic electronic medical record (EMR) sys-
tem after appropriate approval by the Institutional Review Board.
Records were reviewed starting from time of diagnosis to their
last follow up or death. Baseline demographics were recorded,
including other comorbidities. Treatment details, dose reductions,
discontinuation, toxicities, hospitalizations, and date of last follow
up, were all recorded.
Treatment included a two-drug regimen utilizing peme-
trexed 500 mg/m2 and carboplatin area under the curve of five
intravenously (every 3 weeks) until disease progression or in-
tolerance to treatment. Folic acid supplementation (1 mg/day) was
given during the entire course of treatment along withVitamin B12
(1000µg intramuscularly), which was started before the initiation
of chemotherapy and given every 9 weeks thereafter. Response was
graded by the treating oncologist using the RECIST criteria (13)
and verified by source documentation of radiographic readings.
Computed axial tomography (CT) or rarely MRI was obtained
after the first two cycles and subsequently every two to three cycles
of chemotherapy; hence, every 6–9 weeks. Adverse effects were
retrospectively graded from chart records using the NCI criteria
(CTCAE) version 4.
STATISTICAL ANALYSIS
Descriptive statistics, such as median and range, were used to
describe the patient population and follow up. Survival estimates
were calculated using the Kaplan–Meier method. PFS was cal-
culated from the time of initiation of therapy to the time of
progression, death, or last follow up. OS was calculated from the
time of treatment initiation to the time of death or last follow up.
Patients receiving treatment at the time of last follow up had that
as the censoring date for survival analysis.
RESULTS
PATIENT CHARACTERISTICS
Of 86 patients treated with a combination of carboplatin-
pemetrexed in the head and neck cancer clinic at our institution
between January 2008 and December 2012, 63 were included for
this analysis. Twenty-three patients were excluded because their
primary tumor originated in the salivary glands, in the sinus,
nasopharynx, or skin and one patient was excluded because of
a concurrent small cell cancer of the lung.
Median age for this group of patients was 59 years (range, 32–
80 years). Five percent of patients had a new diagnosis of metastatic
disease, 30% had recurrent disease, and 65% had recurrent and
metastatic disease (Table 1). ECOG PS was 0 in 19% (12) of the
patients, 1 in 70% (44) of the patients, and 2 in 11% (7) of the
patients at the time of treatment initiation. Fifty-eight percent of
the patients were current or former smokers. Forty-one percent
of the patients had an oropharyngeal primary of which 50% of
the cancers were HPV related. Carotid involvement was present
in 11% (7) of the patients and two patients died from massive
bleeding during treatment.
Of 63 patients, 77% had prior chemoradiation for management
of locally advanced disease and 21% had been treated with at least
one line of chemotherapy in the palliative setting, prior to the reg-
imen in question (Table 2). Another 8% of the patients received
chemotherapy adjuvantly as part of a clinical trial and 5% were
treated with induction chemotherapy.
TREATMENT CHARACTERISTICS
All patients had a minimum follow up for at least 12 months (range
12–48 months). None of the patients included in this analysis were
on this regimen at the time of data collection. Median number of
cycles administered was 4 (range, 1–14 cycles). Fifteen patients
(24%) progressed on this treatment regimen and did not receive
any more than two cycles.
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Table 1 | Patient characteristics and disease characteristics.
Characteristic Number of patients
Median age, years (Range) 59 (32–80)
Smoking history
Current/former smoker 37
Never/remote smoker 26
Stage of the disease
Recurrent 19
Metastatic 3
Recurrent/metastatic 41
Primary site
Oropharynx 26
Oral cavity 15
Larynx 20
Unknown 2
Sites of involvement
Carotid involvement 7
Regional lymph nodes 40
Lungs 29
Liver 6
Brain 3
Bones 7
HPV status among oropharynx ca
HPV positive 13
HPV negative 4
HPV unknown 9
Two patients passed away from a carotid bleed after just one
cycle of treatment. One patient refused further therapy after one
cycle for unclear reasons. One patient refused further therapy after
three cycles because of fatigue. One patient transferred care after
just one cycle of therapy. One patient had suicidal thoughts and
treatment was with held and patient passed away shortly there-
after. Five of seven patients with PS of 2, demonstrated clinical
deterioration with treatment and just received one to two cycles of
treatment. Six patients received a predetermined number (a total
of four cycles) of carboplatin-pemetrexed after a definitive therapy
to the metastatic site of disease. Ten patients had therapy discon-
tinued to provide a chemo holiday or break from therapy in light
of stable disease or partial response.
RESPONSE AND SURVIVAL ANALYSIS
Response was assessed by the treating oncologists based on radi-
ological studies. Forty-nine percent (31) of the patients achieved
stable disease as their best response, 8% (5) of the patients demon-
strated a partial response, and 24% (15) of the patients progressed
on this therapy. Response could not be assessed in the remain-
ing 12 patients – 2 patients with carotid involvement died from
a massive bleed after just one cycle of therapy. Six patients had
some form of clinical deterioration, which was not directly attrib-
uted to the cancer or the treatment but was likely related to both
and an underlying poor PS and their response to treatment was
not assessed radiologically. One patient was lost to follow up
and another one transferred care, after just one cycle of therapy.
Table 2 |Treatment characteristics.
Characteristic Number of patients
Prior radiation therapy
Yes 13
No 50
Prior surgery
Yes 35*
No 28
Prior chemoradiation
Yes 49
No 14
Prior chemotherapy** (palliative chemo)
1 Line 10
2 Lines 3
Number of cycles treated with
<4 cycles 30
>4 cycles 33
Subsequent lines of treatment
1 Line 20
2 Lines 7
*Four of the 35 surgeries were in fact metastatectomies. One patient had prior
surgery and a metastatectomy as well.
**Another five patients had received chemotherapy in the adjuvant setting as
part of a clinical trial.
One patient refused further treatment after one cycle and another
patient had treatment with held because of suicidal ideation and
these patients did not have a response assessment. On the basis
of Kaplan–Meier analysis, median PFS was 5.1 months (95% CI
3.2, 6.2) and a median OS was 9.4 months (95% CI 4.3, 13.1).
Among patients with the oropharynx as the primary site of dis-
ease (n= 26), median PFS was 6.4 months (95% CI 2.8, 7.9) and
median OS was 16.6 months (95% CI 9.6, 19.5).
In patients with cancers of the oropharynx that were positive
for HPV, median PFS was 7.0 months (95% CI 4.8, ne) and median
OS was 17.1 months (95% CI 11.2, 21.7). Forty-three percent of
the patients moved on to receive another line of therapy upon
disease progression.
SURVIVAL AFTER METASTATECTOMY
Four patients underwent surgical resection to the oligo-metastatic
disease, i.e., metastatectomy. Three out of four patients that under-
went surgical metastatectomy for lung metastasis were alive at the
time of follow up for 2 years from the time of therapy. All three
patients had an oropharyngeal primary.
Another patient who had primary tumor of the oral cavity and
underwent metastatectomy was noted to be deceased 12 months
later. Another patient had definitive radiation to the mediastinal
lymph node, which was the only site of metastatic disease; however,
he was lost to follow up and survival can not be estimated.
TOXICITY
Grade 3 and 4 toxicities attributable to the regimen included
fatigue (14%), neutropenic fever (5%), and hospitalization for
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infections/dehydration in another 16% of the patients. Hospi-
talization for various causes was mostly limited to patients that
started out with a poor PS.
DISCUSSION
In our series, the combination of carboplatin and pemetrexed was
noted to be active and tolerable in patients with metastatic or
recurrent cancers of the head and neck. Even though this treat-
ment was not associated with dramatic responses, it did stabilize
the disease in about 50% of the patients. The PFS and OS seen
with this regimen are encouraging and in the realm of what may
be expected with standard of care. (2). In addition, this regimen is
very well tolerated, fatigue being the only common adverse effect,
especially in patients starting out with a normal PS. The tolera-
bility of this regimen has been very well demonstrated in patients
with NSCLC as well (8). In our experience, outcomes were par-
ticularly good in patients with cancers of the oropharynx and in
those with HPV positivity, which is also in concordance with the
published literature (10, 14).
The relatively modest response rates may be due to the refrac-
tory nature of disease in patients treated with this regimen. As
already detailed above, 77% of the patients had prior treatment
with chemoradiation and 34% of the patients had been treated
with some type of chemotherapy prior to this treatment. As
is noted in a study by Argiris et al., cancers of the oral cav-
ity and hypopharynx, prior radiation treatment, and an ECOG
PS of 1 (versus 0) are independent unfavorable predictors of
objective response (14). Urba et al. had published the results
of a well-conducted phase III study comparing cisplatin versus
cisplatin+ pemetrexed. The trial was overall a negative study;
however, a pre-defined subgroup of patients with oropharyngeal
primary and a good PS did confirm the superiority of this combi-
nation over cisplatin alone. Despite that, this regimen is unlikely
to be ever investigated again in a systematic fashion. At our insti-
tution, we have extensive experience with this regimen given the
excellent tolerability and comparable outcomes to the standard of
care. Most of our experience is with carboplatin (not cisplatin) in
combination with pemetrexed, which may account for better tol-
erability and our ability to treat until disease progression, which
may in fact make this combination more effective.
We at our institution also treat oligo-metastatic disease aggres-
sively, which was observed in this retrospective review as well. Four
patients underwent a surgical metastatectomy and three of those
four patients that had an oropharyngeal primary, were alive at their
last follow up, 24 months from the time of treatment. This phe-
nomenon has recently been reported by other institutions as well
(15).The long-term survival of patients with oligo-metastatic dis-
ease may have impacted the OS for the entire group of patients
with oropharyngeal disease. Also, 27 patients received another
line of therapy, of which seven received two subsequent lines
of therapy at time of disease progression. Of these, 14 patients
had an oropharyngeal primary, once again accounting for the
improvement in OS.
CONCLUSION
Carboplatin-pemetrexed is a feasible, well-tolerated, and effective
regimen in treatment of cancers of the head and neck. There is also
a logistic advantage over other treatment regimens, convenience
being a major factor for many of our patients.
Since the phase III study by Urba et al. was a negative study,
another large study in this population is unlikely, and we strive
to publish our experience and present this as another option in
management of recurrent metastatic disease.
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